Genzyme Allston update at Deutsche Bank (DB)

Deutsche Bank (NYSE: DB) said the FDA cleared 2 remaining lots of finished Cerezyme product for use. The EMEA is evaluating if they will release these lots. The firm believes this is a positive for Genzyme's revenue guidance. Shares are Buy rated.